SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following Q3 revenue announcements and increased FY2025 guidance, with much of the community discussion focused on the potential impact of DefenCath sales and the Melinta acquisition. Some investors are expressing frustration with the stock's performance despite positive news, while others remain optimistic about the company's long-term prospects and potential catalysts, such as a possible deal with DaVita and developments related to TLPH.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is experiencing heightened volatility as investors debate its future trajectory, with some suggesting it's overbought while others point to ongoing global instability and central bank activity as drivers for further gains. Community discussions revolve around potential pullbacks versus continued upward momentum, linking GLD's performance to factors like government shutdowns, trade tensions, and the debasement of fiat currencies. There's also chatter about GLD's relationship with other assets like Bitcoin and US Treasuries.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as investors discuss potential catalysts including multi-year contracts with auto manufacturers and potential government investment. Community members are closely watching for news of asset sales and the impact of steel tariffs, alongside speculation about a foreign partnership. Discussions also revolve around the company's debt and its positioning in the steel market.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

HIMS is trending due to a mix of factors, including a recent CEO stock sale sparking concerns among investors, and broader market reactions to potential shifts in weight-loss drug pricing. The community is actively debating the impact of these events, with some viewing the dip as a buying opportunity and others questioning the company's valuation and leadership. Discussions also include potential short squeeze opportunities and the company's expansion into new markets.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is trending due to a widespread AWS outage impacting numerous services and applications, sparking concerns about the reliability of centralized infrastructure. The community is discussing the extent of the disruption and its potential financial repercussions, while also questioning Amazon's ability to maintain its competitive edge in cloud computing and AI amid the issues.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is trending due to positive Phase 3 trial results for its breast cancer therapy, showing a significant reduction in disease progression. The community is buzzing about the potential for FDA approval and a possible buyout, while some anticipate a potential pullback after the initial surge. Overall sentiment suggests strong conviction in the stock's future, driven by the promising data and potential for the drug to become a new standard of care.

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

RAPT Therapeutics Inc

RAPT Therapeutics is trending following positive Phase II data, leading to a trading halt and sparking community discussion around a potential 'crazy spike' upon unhalting. Bullish sentiment is further fueled by analyst upgrades and price target increases, with some speculating about a potential retail squeeze. The community is also closely watching for further developments regarding RAPT's next-generation CCR4 antagonist.

BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded by Liew Choong-Chin on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.

BioNexus Gene Lab Corp

BioNexus Gene Lab Corp is trending due to a recently announced strategic partnership, sparking excitement among investors. The community is focused on the potential impact of the partnership, especially given the stock's low float and history as a runner. Some traders believe the stock is due for a significant upward move, while others caution about potential dilution and volatility.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL is trending due to positive results from its PATHFINDER 2 study, showcasing increased cancer detection rates with its Galleri blood test, and an upcoming presentation at ESMO. The community is focused on the test's potential for early cancer detection, its impact on survival rates, and the possibility of Medicare coverage. Discussions also involve the stock's valuation relative to potential revenue growth and partnerships.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ ($LAES) is trending following the unveiling of their new Quantum Shield QS7001 chip at a New York conference, sparking excitement about the company's potential in the quantum security space. The community is discussing the chip's hardware-embedded post-quantum cryptography and comparing LAES to other quantum computing stocks, highlighting its strong financials and government contracts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Investing in Progress Software (PRGS)? Don't Miss Assessing Its International Revenue Trends

Explore how Progress Software's (PRGS) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

PRGS vs. INTU: Which Stock Should Value Investors Buy Now?

PRGS vs. INTU: Which Stock Is the Better Value Option?

Should Value Investors Buy Progress Software (PRGS) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Company News for Oct 1, 2025

Companies in The News Are: LW, UNFI, PRGS, ABBV

Progress Software (PRGS) Reports Q3 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Progress Software (PRGS) give a sense of how the business performed in the quarter ended August 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Progress Software (PRGS) Q3 Earnings and Revenues Beat Estimates

Progress Software (PRGS) delivered earnings and revenue surprises of +15.38% and +3.93%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Progress Software Corp. (PRGS), an artificial intelligence-powered application development platform provider, are in the spotlight ahead of its quarterly results.The Burlington, Massachusetts-based company is scheduled to report its financial results for the third quarter of the fiscal year 2025 after the market closes on Monday. According to Fiscal.ai, the company is expected to report adjusted earnings per share (EPS) of $1.30, up from $1.26 reported for the same period in the previous year. Revenue is expected to rise more than 34% year-over-year to $240.11 million.The guidance issued in late June called for adjusted third-quarter EPS of $1.28-$1.34 and revenue of $237 million to $243 million. At that time, the company raised its full-year guidance to $5.28 to $5.40 and $962 million to $974 million, respectively.Among the key metrics the market would look forward to are the annual recurring revenue (ARR) and adjusted operating margin.On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/PRGS">Progress Software stock</a> shifted to ‘bullish’ (73/100) as of early Monday, down from ‘extremely bullish’ the day before. The message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:616/54;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_4_37_47_AM_png_d38f6ad99c.webp" alt="Screenshot 2025-09-29 at 4.37.47 AM.png" width="616" height="54"><figcaption>PRGS sentiment and message volum as of 4:30 a.m. ET, Sept. 29 | source: Stocktwits</figcaption></figure>During the quarter, Progress Software announced AI-powered threat detection and incident response solutions for organizations, as well as a significant expansion of its AI-powered developer capabilities in its developer toolsets, Progress Telerik and Progress Kendo UI. It also unveiled Progress Federal Solutions, a wholly owned subsidiary established to serve the specialized needs of U.S. federal, defense, and public sector organizations.Progress Software stock has lost about 36% this year, underperforming the nearly 6% gain for the&nbsp;<a href="https://stocktwits.com/symbol/XSW">SPDR S&amp;P Software &amp; Services ETF (XSW)</a>. Analysts’ average price target for the stock is $83, according to Koyfin. This implies roughly 67% upside from the stock’s Friday close.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/retail-traders-evenly-split-about-government-shutdown-odds/chDMMmrR37S">Retail Traders Evenly Split About Government Shutdown Odds: Strategists Weigh In On Whether Jobs Report Would Be Delayed Amid Looming Risk</a>

2025/03/06: In this photo illustration, the Progress Software Corporation logo is seen displayed on a smartphone screen. 

Progress Software Analysts Project 67% Upside For Stock: Can Q3 Earnings Spark A Rally

According to Fiscal.ai, the company is expected to report adjusted earnings per share (EPS) of $1.30 and revenue of $240.11 million.

Equity

According to Fiscal.ai, the company is expected to report adjusted earnings per share (EPS) of $1.30 and revenue of $240.11 million.


What Analyst Projections for Key Metrics Reveal About Progress Software (PRGS) Q3 Earnings

Evaluate the expected performance of Progress Software (PRGS) for the quarter ended August 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Adobe Systems (ADBE) Q3 Earnings and Revenues Top Estimates

Adobe (ADBE) delivered earnings and revenue surprises of +2.71% and +1.50%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?

Synopsys (SNPS) Lags Q3 Earnings and Revenue Estimates

Synopsys (SNPS) delivered earnings and revenue surprises of -11.72% and -1.61%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

Progress Software Corp. engages in the provision of products that develop and deploy mission-critical business applications. Its products and solutions include Chef, Corticon, DataDirect, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity & WhatsUp Gold. The company was founded by Joseph Wright Alsop, Clyde Kessel, and Charles Arthur Ziering in 1981 and is headquartered in Burlington, MA.

Progress Software Corp.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$45.16
Prev Close	$44.87
Open	$44.57
Dividend Yield	0.77%
50-Day Moving Average	$44.37
Beta	0.73
Avg. Volume	1.06M
PE Ratio	41.10

52-Week High	$70.56
52-Week Low	$40.29
Market Capitalization	$1.94B
EPS (Annual)	$1.54
Price to Book	4.06
Revenue Per Employee	$267,640.85
Enterprise Value/EBITDA	N/A

PRGS
Progress Software Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PRGS News

PRGSProgress Software Corp.